

# Global Sleep Disorders Drugs and Companies Pipeline Review H1 2017

---

*Sleep Disorders Therapeutics Development and Professional Review Analysis 2017*

PUNE, INDIA, October 13, 2017 /EINPresswire.com/ -- Summary

This report provides an overview of the pipeline landscape for [sleep disorders](#). The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Restless Legs Syndrome, Nocturia and Insomnia, and features dormant and discontinued projects.

Restless Legs Syndrome is a neurologic disorder with a core feature of a distressing, irresistible need or urge to move the legs. Risk factors for RLS include low iron levels, kidney failure, Parkinson's disease, diabetes mellitus, rheumatoid arthritis, and pregnancy.

GET SAMPLE REPORT @ <https://www.wiseguyreports.com/sample-request/2385279-sleep-disorders-drug-development-pipeline-review-2017>

Nocturia, or nocturnal polyuria, describes the excessive urination during night time. Nocturia becomes more common with age and may be symptomatic of the use of diuretic substances, prescription drugs, edema from heart failure, insomnia, pain and prostate or bladder disorders.

Finally, insomnia is a sleep disorder that is characterized by difficulty in falling or staying asleep. Symptoms include difficulty falling asleep at night, waking up during the night, irritability, depression and anxiety.

The size of these pipelines ranges from eight products in restless legs syndrome and nocturia to 31 in insomnia. Across all three of these indications there is a diverse range of molecular targets due to the different pathologies of the indications. The most common targets for restless legs syndrome, nocturia and insomnia therapeutics are D2 dopamine receptor, vasopressin V2 receptor and orexin receptor, respectively.

## Scope

- Which companies are the most active within the pipeline for sleep disorder therapeutics?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in the field of sleep disorders?

## Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and

milestones for each

- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

## Table of Content: Key Points

1	Table of Contents	4
1.1	List of Tables	5
1.2	List of Figures	6
2	Introduction	7
2.1	Sleep Disorders Report Coverage	7
2.2	Restless Legs Syndrome - Overview	7
2.3	Nocturia - Overview	7
2.4	Insomnia - Overview	7
3	Therapeutics Development	8
3.1	Restless Legs Syndrome	8
3.2	Nocturia	11
3.3	Insomnia	14
4	Therapeutics Assessment	21
4.1	Restless Legs Syndrome	21
4.2	Nocturia	27
4.3	Insomnia	33
5	Companies Involved in Therapeutics Development	39
5.1	Restless Legs Syndrome	39
5.2	Nocturia	42
5.3	Insomnia	44
6	Dormant Projects	53
6.1	Restless Legs Syndrome	53
6.2	Nocturia	53
6.3	Insomnia	54
7	Discontinued Products	56
7.1	Restless Legs Syndrome	56
7.2	Insomnia	56
8	Product Development Milestones	58
8.1	Restless Legs Syndrome	58
8.2	Nocturia	63
	...Continued	

Get in touch:

LinkedIn: [www.linkedin.com/company/4828928](http://www.linkedin.com/company/4828928)

Twitter: <https://twitter.com/WiseGuyReports>

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

email us here

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.  
© 1995-2017 IPD Group, Inc. All Right Reserved.